Trung Huynh
Stock Analyst at UBS
(3.60)
# 780
Out of 4,784 analysts
34
Total ratings
61.54%
Success rate
19.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $105 → $110 | $77.69 | +41.59% | 4 | Mar 6, 2025 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $38 | $4.84 | +685.12% | 1 | Feb 13, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $44 | $19.98 | +120.22% | 1 | Feb 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Neutral | $1,130 → $738 | $635.83 | +16.07% | 1 | Jan 16, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $2.36 | +452.02% | 1 | Oct 10, 2024 | |
| CABA Cabaletta Bio | Initiates: Buy | $10 | $1.61 | +521.12% | 1 | Oct 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $54 | $58.90 | -8.32% | 4 | Oct 9, 2024 | |
| LLY Eli Lilly and Company | Assumes: Buy | $612 → $710 | $821.67 | -13.59% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $163.13 | +7.28% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $305.77 | -34.59% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $40 | $25.01 | +59.94% | 4 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $87.60 | +43.84% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $202.72 | -16.14% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.31 | - | 1 | Mar 23, 2021 |
Insmed
Mar 6, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $77.69
Upside: +41.59%
Jasper Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $38
Current: $4.84
Upside: +685.12%
Celldex Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $44
Current: $19.98
Upside: +120.22%
Regeneron Pharmaceuticals
Jan 16, 2025
Downgrades: Neutral
Price Target: $1,130 → $738
Current: $635.83
Upside: +16.07%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $2.36
Upside: +452.02%
Cabaletta Bio
Oct 10, 2024
Initiates: Buy
Price Target: $10
Current: $1.61
Upside: +521.12%
Bristol-Myers Squibb Company
Oct 9, 2024
Maintains: Neutral
Price Target: $50 → $54
Current: $58.90
Upside: -8.32%
Eli Lilly and Company
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $821.67
Upside: -13.59%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $163.13
Upside: +7.28%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $305.77
Upside: -34.59%
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $25.01
Upside: +59.94%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $87.60
Upside: +43.84%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $202.72
Upside: -16.14%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.31
Upside: -